Oligoastrocytoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Mahshid |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and [[corticosteroid]] usage | Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and [[corticosteroid]] usage, checking for signs of [[venous thromboembolism]], regular laboratory tests, and routine imaging (MRI and [[PET|Positron Emission Tomography]]) at scheduled intervals after treatment.<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue= | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079 }} </ref> | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
| Line 14: | Line 14: | ||
*Laboratory tests | *Laboratory tests | ||
**Generally not indicated, unless patient is on [[chemotherapy]] ([[complete blood count]]), [[steroids]] ([[glucose]] level), and [[anticonvulsants]] (complete blood count and [[liver function tests]]) | **Generally not indicated, unless patient is on [[chemotherapy]] ([[complete blood count]]), [[steroids]] ([[glucose]] level), and [[anticonvulsants]] (complete blood count and [[liver function tests]]) | ||
*MRI every 3-4 months | *[[MRI]] every 3-4 months | ||
**Evaluation of tumor extension on T2 fluid-attenuated inversion recovery (FLAIR)-weighted [[MRI]] | |||
*[[PET|Positron emission tomography]] | *[[PET|Positron emission tomography]] | ||
**To differentiate [[tumor]] recurrence from radiation-induced tumor [[necrosis]] | **To differentiate [[tumor]] recurrence from radiation-induced tumor [[necrosis]] | ||
| Line 26: | Line 27: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 14:43, 27 November 2017
|
Oligoastrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligoastrocytoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Oligoastrocytoma secondary prevention |
|
Risk calculators and risk factors for Oligoastrocytoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Secondary prevention strategies following oligoastrocytoma include a clinical assessment of neurological function and corticosteroid usage, checking for signs of venous thromboembolism, regular laboratory tests, and routine imaging (MRI and Positron Emission Tomography) at scheduled intervals after treatment.[1]
Secondary Prevention
Follow up after treatment
Patients treated for oligoastrocytoma should follow-up for secondary prevention. Follow-up measures for oligoastrocytoma include:[1]
- Clinical assessment of neurological function
- Tapering steroid usage as early as possible
- Checking for signs of venous thromboembolism
- Laboratory tests
- Generally not indicated, unless patient is on chemotherapy (complete blood count), steroids (glucose level), and anticonvulsants (complete blood count and liver function tests)
- MRI every 3-4 months
- Evaluation of tumor extension on T2 fluid-attenuated inversion recovery (FLAIR)-weighted MRI
- Positron emission tomography
References
- ↑ 1.0 1.1 Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). "High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.